Claims
- 1. A wound dressing comprising a physiologically compatible, open-celled, hydrophilic polyether polyurethane foam derived from a foamable composition comprising a polyether polyol component containing ethylene oxide groups and having an absorptive capacity greater than 10 times its own weight, as determined when foam cells adjacent one surface of the foam material have been irreversibly partially collapsed relative to foam cells remote from the said surface.
- 2. A dressing as claimed in claim 1, in which said foam material is derived from a foamable composition comprising a polyol component constituted by a polyether polyol containing ethylene oxide groups and a branched ethylene oxide modified polyether polyol in a ratio of from 65 to 85:35 to 15 parts by weight.
- 3. A dressing as claimed in claim 1 in which said foam material also comprises an impregnated haemostatic composition comprising a major proportion of an impregnant alginic acid and the salts thereof.
- 4. A dressing as carried in claim 3, in which said haemostatic composition comprises calcium alginate and sodium alginate in a ratio of from 90 to 70:10 to 30 parts by weight.
- 5. A dressing as claimed in claim 3, in which the haemostatic composition is present in an amount of at least 60 g/m.sup.2 on a dry basis.
- 6. A dressing as claimed in claim 1, in which foam cells adjacent one surface of the foam material are irreversibly partially collapsed relative to foam cells remote from said surface to reduce adherency to a healing wound.
- 7. A dressing as claimed in claim 1 and further comprising a gas- and moisture-permeable backing layer for the exclusion of bacteria.
- 8. A dressing as claimed in claim 1 in which said foam material is in the form of a pad and which further comprises an adhesive sheet or panel strip extending over the back of said pad and beyond at least part of the perimeter thereof.
- 9. A dressing as claimed in claim 8 and further comprising a layer, of absorbent for offensive odor emanating from a wound.
- 10. A method of dressing a wound comprising the step of applying to the wound a physiologically compatible, open-celled, hydrophilic polyether polyurethane foam material derived from a foamable composition comprising a polyether polyol component containing ethylene oxide groups and having an absorptive capacity greater than 10 times its own weight, as determined when foam cells adjacent one surface of the foam material have been irreversibly partially collapsed relative to foam cells remote from the said surface.
- 11. A method as claimed in claim 10, in which said foam material is derived from a foamable composition comprising a polyol component constituted by a polyether polyol containing ethylene oxide groups and a branched ethylene oxide modified polyether polyol in a ratio of from 65 to 85:35 to 15 parts by weight.
- 12. A method as claimed in claim 1, in which said foam material also comprises an impregnated haemostatic composition comprising a major proportion of an impregnant selected from the group consisting of alginic acid and the salts thereof.
- 13. A method as claimed in claim 12, in which said haemostatic composition comprises calcium alginate and sodium alginate in a ratio of from 90 to 70:10 to 30 parts by weight.
- 14. A method as claimed in claim 12, in which the haemostatic composition is present in an amount of at least 60 g/m.sup.2 on a dry basis.
- 15. A method as claimed in claim 10, in which foam cells adjacent one surface of the foam material are irreversibly partially collapsed relative to foam cells remote from said surface to reduce adherency to a healing wound.
- 16. A method as claimed in claim 10, in which said foam material further comprises a gas- and moisture-permeable backing layer for the exclusion of bacteria.
- 17. A method as claimed in claim 10, in which said foam material is in the form of a pad and further comprises an adhesive sheet or panel strip extending over the back of said pad and beyond at least part of the perimeter thereof.
- 18. A method as claimed in claim 17, in which said pad further comprises a layer of absorbent for offensive odor emanating from said wound.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9102660 |
Feb 1991 |
GBX |
|
Parent Case Info
This is a continuation application of application Ser. No. 08/433,950, filed May 4, 1995, now abandoned, which, in turn, is a continuation of application Ser. No. 08/098,336, filed Feb. 3, 1994, now abandoned, which, in turn, is a national stage filing of PCT/GB92/00231, filed on Feb. 7, 1992, which, in turn, is based on United Kingdom Application Ser. No. 9102660.9, filed on Feb. 7, 1991.
US Referenced Citations (6)
Foreign Referenced Citations (32)
Number |
Date |
Country |
0041934 |
Dec 1981 |
EPX |
0053936 |
Jun 1982 |
EPX |
0092999 |
Nov 1983 |
EPX |
0117438 |
Sep 1984 |
EPX |
0196364 |
Oct 1986 |
EPX |
0209142 |
Jan 1987 |
EPX |
0267051 |
May 1988 |
EPX |
0272918 |
Jun 1988 |
EPX |
0279118 |
Aug 1988 |
EPX |
0299122 |
Jan 1989 |
EPX |
0327328 |
Aug 1989 |
EPX |
0335669 |
Oct 1989 |
EPX |
0629419 |
Sep 1949 |
GBX |
0696309 |
Aug 1953 |
GBX |
0816854 |
Jul 1959 |
GBX |
1001912 |
Aug 1965 |
GBX |
1306508 |
Feb 1973 |
GBX |
1378931 |
Dec 1974 |
GBX |
1417962 |
Dec 1975 |
GBX |
1570485 |
Jul 1980 |
GBX |
2048070 |
Dec 1980 |
GBX |
1583367 |
Jan 1981 |
GBX |
1594389 |
Jul 1981 |
GBX |
1602858 |
Nov 1981 |
GBX |
2083487 |
Mar 1982 |
GBX |
2093702 |
Sep 1982 |
GBX |
2093703 |
Sep 1982 |
GBX |
2102012 |
Jan 1983 |
GBX |
2134792 |
Aug 1984 |
GBX |
2207865 |
Feb 1989 |
GBX |
2221620 |
Jan 1990 |
GBX |
2228682 |
Sep 1990 |
GBX |
Non-Patent Literature Citations (1)
Entry |
Turner, T.D., Proceedings of a Symposium on Wound Healing (Sundell B. ed.) pp. 75-84 (1978). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
433950 |
May 1995 |
|
Parent |
098336 |
|
|